145 related articles for article (PubMed ID: 11190709)
21. Consolidative abdominopelvic radiotherapy after surgery and carboplatin/paclitaxel chemotherapy for epithelial ovarian cancer.
Dinniwell R; Lock M; Pintilie M; Fyles A; Laframboise S; Depetrillo D; Levin W; Manchul L; Murphy J; Oza A; Rosen B; Sturgeon J; Milosevic M
Int J Radiat Oncol Biol Phys; 2005 May; 62(1):104-10. PubMed ID: 15850909
[TBL] [Abstract][Full Text] [Related]
22. Adverse affects of paclitaxel and carboplatin combination chemotherapy in epithelial gynecologic cancer.
Kietpeerakool C; Suprasert P; Srisomboon J
J Med Assoc Thai; 2005 Mar; 88(3):301-6. PubMed ID: 15962635
[TBL] [Abstract][Full Text] [Related]
23. Activity of chemotherapy in mucinous epithelial ovarian cancer: a retrospective study.
Pisano C; Greggi S; Tambaro R; Losito S; Iodice F; Di Maio M; Ferrari E; Falanga M; Formato R; Iaffaioli VR; Pignata S
Anticancer Res; 2005; 25(5):3501-5. PubMed ID: 16101169
[TBL] [Abstract][Full Text] [Related]
24. Improved tolerance of primary chemotherapy with reduced-dose carboplatin and paclitaxel in elderly ovarian cancer patients.
Fader AN; von Gruenigen V; Gibbons H; Abushahin F; Starks D; Markman M; Belinson J; Rose P
Gynecol Oncol; 2008 Apr; 109(1):33-8. PubMed ID: 18261784
[TBL] [Abstract][Full Text] [Related]
25. The combination of monthly carboplatin and weekly paclitaxel is highly active for the treatment of recurrent ovarian cancer.
Hoekstra AV; Hurteau JA; Kirschner CV; Rodriguez GC
Gynecol Oncol; 2009 Dec; 115(3):377-81. PubMed ID: 19800107
[TBL] [Abstract][Full Text] [Related]
26. [Adverse effect of paclitaxel plus carboplatin combination therapy related to administration schedule in patients with ovarian cancer].
Fuse K; Tanaka T; Kagaya H; Suzuki T; Kimura A
Gan To Kagaku Ryoho; 2001 Sep; 28(9):1295-7. PubMed ID: 11579644
[No Abstract] [Full Text] [Related]
27. A phase I/II study of carboplatin and paclitaxel in patients with epithelial ovarian cancer.
Yamamoto R; Minobe S; Kaneuchi M; Sakuragi N; Fujimoto S; Ishizaki Y; Domon H; Hareyama H; Sato C; Fujino T; Kawaguchi I; Yamaguchi T; Fujimoto T; Yoshiaki K
Jpn J Clin Oncol; 2002 Apr; 32(4):128-34. PubMed ID: 12072422
[TBL] [Abstract][Full Text] [Related]
28. Clinical trial and pharmacokinetic study of combination paclitaxel and carboplatin in patients with epithelial ovarian cancer.
Yamamoto R; Kaneuchi M; Nishiya M; Todo Y; Takeda M; Okamoto K; Negishi H; Sakuragi N; Fujimoto S; Hirano T
Cancer Chemother Pharmacol; 2002 Aug; 50(2):137-42. PubMed ID: 12172979
[TBL] [Abstract][Full Text] [Related]
29. Phase I study of alternating doublets of topotecan/carboplatin and paclitaxel/carboplatin in patients with newly diagnosed, advanced ovarian cancer.
Gordon AN; Hancock KC; Matthews CM; Messing M; Stringer CA; Doherty MG; Teneriello M
Gynecol Oncol; 2002 Apr; 85(1):129-35. PubMed ID: 11925132
[TBL] [Abstract][Full Text] [Related]
30. A pilot trial of TAC (paclitaxel, doxorubicin, and carboplatin) chemotherapy with filgastrim (r-metHuG-CSF) support followed by radiotherapy in patients with "high-risk" endometrial cancer.
Duska LR; Berkowitz R; Matulonis U; Muto M; Goodman A; McIntyre JF; Klein A; Atkinson T; Seiden MV; Campos S
Gynecol Oncol; 2005 Jan; 96(1):198-203. PubMed ID: 15589601
[TBL] [Abstract][Full Text] [Related]
31. A feasibility study of paclitaxel and carboplatin therapy in Japanese patients with epithelial ovarian cancer.
Takei Y; Suzuki M; Ohwada M; Saga Y; Kohno T; Machida S; Sato I
Oncol Rep; 2003; 10(4):951-5. PubMed ID: 12792751
[TBL] [Abstract][Full Text] [Related]
32. Addition of epirubicin as a third drug to carboplatin-paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens.
du Bois A; Weber B; Rochon J; Meier W; Goupil A; Olbricht S; Barats JC; Kuhn W; Orfeuvre H; Wagner U; Richter B; Lueck HJ; Pfisterer J; Costa S; Schroeder W; Kimmig R; Pujade-Lauraine E; ; ;
J Clin Oncol; 2006 Mar; 24(7):1127-35. PubMed ID: 16505432
[TBL] [Abstract][Full Text] [Related]
33. Weekly paclitaxel and carboplatin (PC-W) for patients with primary advanced ovarian cancer: results of a multicenter phase-II study of the NOGGO.
Sehouli J; Stengel D; Mustea A; Camara O; Keil E; Elling D; Ledwon P; Christiansen B; Klare P; Gebauer G; Schwarz M; Lichtenegger W;
Cancer Chemother Pharmacol; 2008 Feb; 61(2):243-50. PubMed ID: 17393164
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of weekly low-dose paclitaxel and carboplatin treatment for patients with platinum-sensitive relapsed ovarian cancer.
Watanabe Y; Nakai H; Ueda H; Hoshiai H
Gynecol Oncol; 2005 Feb; 96(2):323-9. PubMed ID: 15661216
[TBL] [Abstract][Full Text] [Related]
35. Four cycles of paclitaxel and carboplatin as adjuvant treatment in early-stage ovarian cancer: a six-year experience of the Hellenic Cooperative Oncology Group.
Bamias A; Papadimitriou C; Efstathiou E; Rodolakis A; Vlahos G; Voulgaris Z; Bozas G; Fountzilas G; Aravantinos G; Razis E; Gika D; Dimopoulos MA
BMC Cancer; 2006 Sep; 6():228. PubMed ID: 16999858
[TBL] [Abstract][Full Text] [Related]
36. A phase II trial of weekly paclitaxel and every 3 weeks of carboplatin in potentially platinum-sensitive ovarian and peritoneal carcinoma.
Rose PG; Smrekar M; Fusco N
Gynecol Oncol; 2005 Feb; 96(2):296-300. PubMed ID: 15661211
[TBL] [Abstract][Full Text] [Related]
37. Carboplatin and paclitaxel versus cisplatin, paclitaxel and doxorubicin for first-line chemotherapy of advanced ovarian cancer: a Hellenic Cooperative Oncology Group (HeCOG) study.
Aravantinos G; Fountzilas G; Bamias A; Grimani I; Rizos S; Kalofonos HP; Skarlos DV; Economopoulos T; Kosmidis PA; Stathopoulos GP; Briasoulis E; Pectasides D; Samantas E; Timotheadou E; Papadimitriou C; Papanikolaou A; Onyenadum A; Papakostas P; Bafaloukos D; Dimopoulos MA;
Eur J Cancer; 2008 Oct; 44(15):2169-77. PubMed ID: 18691879
[TBL] [Abstract][Full Text] [Related]
38. [Paclitaxel plus carboplatin in ovarian cancer-comparison of adverse effects between monthly and weekly administration].
Kumagai M; Fujii T; Komatsu M; Kusuda T; Takehara K; Shinkou S; Naitou H
Gan To Kagaku Ryoho; 2004 Apr; 31(4):555-9. PubMed ID: 15114699
[TBL] [Abstract][Full Text] [Related]
39. Paclitaxel 175 or 225 mg per meters squared with carboplatin in advanced ovarian cancer: a randomized trial.
Bolis G; Scarfone G; Polverino G; Raspagliesi F; Tateo S; Richiardi G; Melpignano M; Franchi M; Mangili G; Presti M; Villa A; Conta E; Guarnerio P; Cipriani S; Parazzini F
J Clin Oncol; 2004 Feb; 22(4):686-90. PubMed ID: 14966092
[TBL] [Abstract][Full Text] [Related]
40. Phase II study of sequential doublets: topotecan and carboplatin, followed by paclitaxel and carboplatin, in patients with newly diagnosed advanced ovarian cancer.
Gordon AN; Asmar L; Messing MJ; Street DG; Pippitt CH; Bailey CL; Savage J; Young JA
Gynecol Oncol; 2004 Aug; 94(2):533-9. PubMed ID: 15297200
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
